BASF
Search results
6 days ago · Bayer has advanced its small-molecule drug BAY 2927088 into phase 3 for non-small cell lung cancer (NSCLC) with HER2 activating mutations, one of the drugs central to the company’s plan to...
Sep 9, 2024 · BAY 2927088 is an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant human epidermal growth factor receptors 2 (HER2), including HER2 exon 20 insertions and HER2 point mutations, as well as epidermal growth factor receptors (EGFR), with high selectivity for mutant vs wild-type EGFR.
Sep 26, 2024 · As a leader in healthcare, Bayer provides innovative solutions designed to prevent, alleviate and treat diseases.
3 days ago · Bayer Ag BAYRY and its wholly owned subsidiary BlueRock Therapeutics LP announced positive 24-month data from an early-stage study on experimental candidate bemdaneprocel (BRT-DA01)....
6 days ago · Today, Bayer Healthcare concentrates on five big therapeutic groups: cardiovascular and blood diseases, oncological disease, ophthalmology, women’s healthcare and imaging techniques.
Sep 26, 2024 · The launch of Bayer Co.Lab Shanghai underscores Bayer's continued commitment to investing in innovation in China and reinforces its determination to grow in this key market. Through Bayer Co.Lab, Bayer will deepen local partnerships and accelerate co-creation in China to drive healthcare innovation in China and globally.
20 hours ago · The Latest. Bayer has revealed the results of its phase 3 FINEARTS-HF trial for its nonsteroidal mineralocorticoid receptor antagonist Kerendia. Originally approved for use in patients with chronic kidney disease (CKD) associated with Type 2 diabetes (T2D), Bayer has been determined to expand its market to treat patients with heart failure (HF).
